[EN] BETA-2 SELECTIVE ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DE RÉCEPTEUR ADRÉNERGIQUE BÊTA-2 SÉLECTIF
申请人:UNIV LELAND STANFORD JUNIOR
公开号:WO2019112913A1
公开(公告)日:2019-06-13
Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate β2AR with high selectivity over β1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective β-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.